InTandem Capital Partners closes Fund III at $715m

Private Equity Wire

InTandem Capital Partners, a middle-market private equity firm focused on healthcare services, has held the final closing of InTandem Capital Partners Fund III, at $715m, above its original target of $650m.

Consistent with its predecessor funds, Fund III will continue the firm’s well-established strategy of making control investments in North American payor, provider, and pharmaceutical services businesses.

Fund III secured commitments from a globally diversified group of existing and new investors, including leading endowments, foundations, family offices, healthcare and pension systems, and financial institutions.

The Fund is already actively investing, having recently completed its third platform deal in Adams Clinical, a multi-site clinical research management organisation focused on late-stage outpatient central nervous system trials.

Kirkland and Ellis LLP served as legal counsel for Fund III and Raymond James acted as placement agent.

The full article is available here. This article was published at Private Equity Wire.